Literature DB >> 520477

Modification by levo-propranolol of tremors induced by harmine in mice.

S K Kulkarni, P N Kaul.   

Abstract

It has been recently reported that the levo isomer of propranolol possesses anti-serotonin properties in animals. Since harmine-induced behavioural changes in mice are reported to be mediated through central serotonergic receptors, an attempt was made to test whether 1-propranolol would also modify harmine-induced responses by virtue of its anti-serotonergic or anti-adrenergic property. The results indicated that l- and dl-propranolol inhibited central serotonin receptor mediated responses to harmine in mice, a finding that is analogous to other recent observations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 520477     DOI: 10.1007/BF01953232

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  7 in total

1.  (-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system.

Authors:  A R Green; D G Grahame-Smith
Journal:  Nature       Date:  1976-08-12       Impact factor: 49.962

2.  Serotonin-like actions of quipazine on the central nervous system.

Authors:  R Rodríguez; J A Rojas-Ramírez; R R Drucker-Colín
Journal:  Eur J Pharmacol       Date:  1973-11       Impact factor: 4.432

3.  Mechanisms of tremor induction by harmine.

Authors:  D M Kelly; R J Naylor
Journal:  Eur J Pharmacol       Date:  1974-06       Impact factor: 4.432

4.  Further studies with propranolol in psychotic patients. Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion.

Authors:  A Atsmon; I Blum; M Steiner; A Latz; H Wijsenbeek
Journal:  Psychopharmacologia       Date:  1972

5.  Abnormal movements and rigidity induced by harmaline in relation to striatal acetylcholine, serotonin, and dopamine.

Authors:  J S Kim; R Hassler; M Kurokawa; I J Bak
Journal:  Exp Neurol       Date:  1970-11       Impact factor: 5.330

6.  Similarities between the pharmacological actions of quipazine and serotonin.

Authors:  E Hong; L F Sancilio; R Vargas; E G Pardo
Journal:  Eur J Pharmacol       Date:  1969       Impact factor: 4.432

7.  Beta-adrenoceptor blocking agents and responses to adrenaline and 5-hydroxytryptamine in rat isolated stomach and uterus.

Authors:  Y Schechter; M Weinstock
Journal:  Br J Pharmacol       Date:  1974-10       Impact factor: 8.739

  7 in total
  5 in total

Review 1.  Knowledge gaps and research recommendations for essential tremor.

Authors:  Franziska Hopfner; Dietrich Haubenberger; Wendy R Galpern; Katrina Gwinn; Ashlee Van't Veer; Samantha White; Kailash Bhatia; Charles H Adler; David Eidelberg; William Ondo; Glenn T Stebbins; Caroline M Tanner; Rick C Helmich; Fred A Lenz; Roy V Sillitoe; David Vaillancourt; Jerrold L Vitek; Elan D Louis; Holly A Shill; Matthew P Frosch; Tatiana Foroud; Gregor Kuhlenbäumer; Andrew Singleton; Claudia M Testa; Mark Hallett; Rodger Elble; Günther Deuschl
Journal:  Parkinsonism Relat Disord       Date:  2016-10-04       Impact factor: 4.891

2.  Raphe - cerebellum interactions. I. Effects of cerebellar stimulation and harmaline administration on single unit activity of midbrain raphe neurons in the rat.

Authors:  M Weiss; J Pellet
Journal:  Exp Brain Res       Date:  1982       Impact factor: 1.972

3.  Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.

Authors:  Marlaina R Stocco; Cole Tolledo; Fariba Baghai Wadji; Frank J Gonzalez; Sharon Miksys; Rachel F Tyndale
Journal:  Mol Neurobiol       Date:  2020-08-06       Impact factor: 5.590

4.  Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor.

Authors:  Adrian Handforth
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-12

5.  Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy.

Authors:  Katharina E Meijboom; Viola Volpato; Jimena Monzón-Sandoval; Joseph M Hoolachan; Suzan M Hammond; Frank Abendroth; Olivier G de Jong; Gareth Hazell; Nina Ahlskog; Matthew Ja Wood; Caleb Webber; Melissa Bowerman
Journal:  JCI Insight       Date:  2021-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.